Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
Saved in:
| Title: | Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. |
|---|---|
| Authors: | Buzdar A; The University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA. abuzdar@mdanderson.org, Hayes D, El-Khoudary A, Yan S, Lønning P, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, Eisenber P |
| Corporate Authors: | Droloxifene 301 Study Group |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2002 May; Vol. 73 (2), pp. 161-75. |
| Publication Type: | Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print Cited Medium: Print ISSN: 0167-6806 (Print) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
